Sign up to save your podcasts
Or
Share Therapeutic Mechanisms Debuting in April 2026 Glaucoma Trials
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Therapeutic Mechanisms Debuting in April 2026 Glaucoma Trials
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/therapeutic-mechanisms-debuting-in-april-2026-glaucoma-trials
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Introduction
Glaucoma is a chronic eye disease in which pressure buildup (intraocular pressure, or IOP) damages the optic nerve, leading to vision loss. Standard treatments focus on lowering IOP by helping fluid drain out of the eye or reducing fluid production. In 2026, several new clinical trials are testing novel approaches beyond the usual medications. These include drugs and devices that enhance outflow, suppress inflow, prevent scarring (anti-fibrotics), protect the optic nerve (neuroprotective), and improve blood flow to the nerve (vascular modulators). Each strategy has a clear laboratory rationale and often positive early human data. For example, nitric-oxide–donating prostaglandins (like NCX 470) and Rho-kinase (ROCK) inhibitors aim to widen the trabecular meshwork or veins to enhance drainage () (). Neuroprotective strategies (such as high-dose vitamin B3 or GLP-1 agonists) have shown in animal models that they can preserve retinal nerve cells even without pressure changes () (). Below we summarize each mechanism, its rationale, early evidence, and how trials measure success (e.g., IOP patterns, nerve imaging or visual fields), along with key safety issues.
Outflow Enhancers
What it is. These treatments aim to improve fluid drainage through the eye’s natural outflow channels (trabecular meshwork and Schlemm’s canal) or add new paths. Enhanced outflow lowers IOP without directly reducing fluid production. Examples include new eyedrop drugs and micro-invasive surgical devices.
Rationale (preclinical and early data). Preclinical studies show that relaxing the trabecular meshwork or dilating outflow veins can dramatically increase fluid outflow. For instance, rock inhibitors like netarsudil relax cellular tension in the drainage tissue – in clinical trials they lowered IOP as well as timolol (a gold-standard medicine) (). Another example is QLS-111, an ATP-sensitive potassium-channel opener that dilates veins and may reduce the downstream pressure on Schlemm’s canal (). In Phase II human trials, QLS-111 added to latanoprost dropped IOP by several mmHg (). Device approaches (like suprachoroidal implants or laser trabeculoplasty) physically widen or reopen drainage channels, and early studies in animals and humans show pressure falls and improved outflow on imaging.
... Continue reading at https://visualfieldtest.com/en/therapeutic-mechanisms-debuting-in-april-2026-glaucoma-trials
Support the show
View all episodes
By VisualFieldTest.comThis audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/therapeutic-mechanisms-debuting-in-april-2026-glaucoma-trials
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Introduction
Glaucoma is a chronic eye disease in which pressure buildup (intraocular pressure, or IOP) damages the optic nerve, leading to vision loss. Standard treatments focus on lowering IOP by helping fluid drain out of the eye or reducing fluid production. In 2026, several new clinical trials are testing novel approaches beyond the usual medications. These include drugs and devices that enhance outflow, suppress inflow, prevent scarring (anti-fibrotics), protect the optic nerve (neuroprotective), and improve blood flow to the nerve (vascular modulators). Each strategy has a clear laboratory rationale and often positive early human data. For example, nitric-oxide–donating prostaglandins (like NCX 470) and Rho-kinase (ROCK) inhibitors aim to widen the trabecular meshwork or veins to enhance drainage () (). Neuroprotective strategies (such as high-dose vitamin B3 or GLP-1 agonists) have shown in animal models that they can preserve retinal nerve cells even without pressure changes () (). Below we summarize each mechanism, its rationale, early evidence, and how trials measure success (e.g., IOP patterns, nerve imaging or visual fields), along with key safety issues.
Outflow Enhancers
What it is. These treatments aim to improve fluid drainage through the eye’s natural outflow channels (trabecular meshwork and Schlemm’s canal) or add new paths. Enhanced outflow lowers IOP without directly reducing fluid production. Examples include new eyedrop drugs and micro-invasive surgical devices.
Rationale (preclinical and early data). Preclinical studies show that relaxing the trabecular meshwork or dilating outflow veins can dramatically increase fluid outflow. For instance, rock inhibitors like netarsudil relax cellular tension in the drainage tissue – in clinical trials they lowered IOP as well as timolol (a gold-standard medicine) (). Another example is QLS-111, an ATP-sensitive potassium-channel opener that dilates veins and may reduce the downstream pressure on Schlemm’s canal (). In Phase II human trials, QLS-111 added to latanoprost dropped IOP by several mmHg (). Device approaches (like suprachoroidal implants or laser trabeculoplasty) physically widen or reopen drainage channels, and early studies in animals and humans show pressure falls and improved outflow on imaging.
... Continue reading at https://visualfieldtest.com/en/therapeutic-mechanisms-debuting-in-april-2026-glaucoma-trials
Support the show